| Literature DB >> 34065599 |
Tuan-Jen Fang1,2, Yu-Cheng Pei2,3,4,5, Yi-An Lu1, Hsiu-Feng Chung1, Hui-Chen Chiang6, Hsueh-Yu Li1,2, Alice M K Wong2,3,4,5.
Abstract
(1) Background: severe weight loss was reported to be related to unilateral vocal fold paralysis (UVFP) after esophagectomy and could thus impair survival. Concomitant radical lymph node dissection along the recurrent laryngeal nerve during esophageal cancer surgery is controversial, as it might induce UVFP. Early intervention for esophagectomy-related UVFP by administering intracordal injections of temporal agents has recently become popular. This study investigated the survival outcomes of esophagectomy for esophageal squamous cell carcinoma (ESCC) after the introduction of early injection laryngoplasty (EIL). (2)Entities:
Keywords: esophageal cancer; esophagectomy; injection laryngoplasty; survival; unilateral vocal fold paralysis
Year: 2021 PMID: 34065599 PMCID: PMC8160664 DOI: 10.3390/diagnostics11050914
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Patient characteristics of the enrolled group.
| All | Non-UVFP * | UVFP |
| |
|---|---|---|---|---|
| Sex (male/female) | 339/19 | 300/16 | 39/3 | 0.459 |
| Age (years) | 55.42 ± 9.41 | 55.50 ± 9.61 | 54.63 ± 7.39 | 0.665 |
| Paralysis | 316 | 42 | ||
| Side (left/right) | 36/6 | |||
| Hyaluronate injection (Y/N) | 31/11 | |||
| Recovery (Y/N) | 4/38 | |||
| Thoracic anastomosis/cervical anastomosis | 115/241 | 112/204 | 3/39 | 0.000 |
| Thoracotomy/MIE ** | 82/274 | 81/235 | 1/41 | |
| Stage | 11 | 9 | 3 | |
| IA | ||||
| IB | 23 | 21 | 2 | |
| IIA | 20 | 16 | 4 | |
| IIB | 54 | 48 | 6 | |
| IIIA | 90 | 80 | 80 | |
| IIIB | 79 | 70 | 70 | |
| IIIC | 63 | 57 | 57 | |
| IV | 14 | 14 | 0 | |
| Unknown | 2 | 1 | 1 | |
| Alive/dead | 147/209 | 123/193 | 25/17 |
* UVFP: unilateral vocal fold paralysis; ** MIE: minimally invasive esophagectomy.
Figure 1Overall (A) and disease-free (B) survival of patients after esophagectomy. Patients with unilateral vocal fold paralysis had a significantly better survival rate than those without vocal fold paralysis.
Figure 2The overall survival is better in groups that received neck anastomosis (A), had stage I or II disease (B) and underwent minimally invasive esophagectomy (C).
Multivariate analysis of the factors influencing overall survival after esophagectomy.
| HR | 95% CI |
| ||
|---|---|---|---|---|
| Vocal fold motility | Palsy | 1 | 0.889–2.454 | 0.133 |
| Intact | 1.48 | |||
| Surgical procedure | MIE | 1 | 1.408–3.072 | <0.001 |
| Open | 2.08 | |||
| Stage | I, II | 1 | 1.243–2.375 | 0.001 |
| III, IV | 1.72 | |||
| Anastomosis | Cervical | 0.91 | 0.626–1.311 | 0.600 |
| Thoracic | 1 | |||
Figure 3From 2011 to 2016, the number of injection laryngoplasty procedures for unilateral vocal fold paralysis has increased, and this procedure is now performed earlier.
Comparison of the characteristics of patients with UVFP who did or did not undergo immediate injection laryngoplasty.
| Parameters | |||
|---|---|---|---|
| HA Injection | No HA Injection | ||
| Glottal gap | |||
| Closed-phase NGGA | 11.67 ± 12.80 | 3.11 ± 4.09 | 0.037 * |
| 20.55 ± 12.93 | 0.072 | ||
| 8.87 ± 6.21 | 0.705 | ||
| LEMG | |||
| Normal side of TA-LCA (turn/s) | 1112.92 ± 410.48 | 904.39 ± 277.32 | 0.131 |
| Lesion side of TA-LCA (turn/s) | 297.20 ± 227.69 | 582.73 ± 634.41 | 0.173 |
| Turn ratio of TA-LCA | 0.33 ± 0.31 | 0.69 ± 0.72 | 0.034 * |
| 914.05 ± 346.93 | 0.531 | ||
| 704.05 ± 301.44 | 0.814 | ||
| 0.83 ± 0.38 | 0.510 | ||
| Voice laboratory analysis | |||
| Maximum phonation time (s) | 3.93 ± 2.84 | 10.83 ± 7.34 | 0.016 * |
| SZ ratio | 2.05 ± 1.03 | 1.41 ± 0.93 | 0.097 |
| Fundamental frequency (Hz) | 156.97 ± 51.97 | 131.62 ± 37.71 | 0.197 |
| Jitter (%) | 5.18 ± 5.35 | 1.71 ± 1.12 | 0.051 |
| Shimmer (dB) | 0.98 ± 0.65 | 0.48 ± 0.29 | 0.024 * |
| Harmonic-to-noise ratio | 5.15 ± 2.99 | 7.37 ± 5.79 | 0.128 |
| Vos | |||
| Voice outcome survey score | 30.71 ± 12.15 | 58.50 ± 24.04 | 0.005 ** |
| SF-36 | |||
| Physical functioning | 60.36 ± 25.27 | 80.50 ± 13.22 | 0.003 ** |
| Role limitation due to physical health | 16.96 ± 34.06 | 30.00 ± 43.78 | 0.342 |
| Role limitation due to emotional problem | 30.92 ± 40.50 | 70.00 ± 42.89 | 0.014 * |
| Vitality | 47.50 ± 21.54 | 54.50 ± 11.65 | 0.337 |
| Mental health | 63.29 ± 18.60 | 64.80 ± 13.96 | 0.816 |
| Social functioning | 47.45 ± 25.51 | 65.00 ± 26.87 | 0.074 |
| Bodily pain | 63.61 ± 24.91 | 74.75 ± 25.51 | 0.235 |
| General health perceptions | 41.79 ± 22.53 | 55.00 ± 19.72 | 0.110 |
* p < 0.05, ** p < 0.01.
The change of parameters in the comprehensive voice assessment after HIL.
| Parameters | Baseline (a) | 1 Month Post HIL (b) | 3 Month Post HIL (c) | 6 Month Post HIL (d) | Significant Comparison † | |
|---|---|---|---|---|---|---|
| Glottal gap | ||||||
| Closed-phase NGGA | 11.3751 ± 12.4384 | 2.0742 ± 2.1528 | 4.844 ± 4.598 | 2.9502 ± 4.2794 | 0.009 ** | ab, ac, ad |
| Voice laboratory analysis | ||||||
| Maximum phonation time (s) | 3.8067 ± 2.7767 | 7.5948 ± 6.1624 | 7.2396 ± 6.0317 | 7.5043 ± 5.9946 | <0.001 *** | ab, ac, ad |
| SZ ratio | 2.1704 ± 1.1316 | 1.4734 ± 0.9986 | 1.6349 ± 1.0143 | 1.6355 ± 1.2799 | 0.072 | ab |
| Fundamental frequency (Hz) | 154.8151 ± 51.1644 | 142.7253 ± 32.9603 | 144.229 ± 34.116 | 146.8968 ± 38.6546 | 0.774 | |
| Jitter (%) | 5.1929 ± 5.1651 | 1.988 ± 1.043 | 2.8703 ± 1.9116 | 2.2739 ± 1.5287 | 0.050 | ab |
| Shimmer (dB) | 1.008 ± 0.6403 | 0.4184 ± 0.17 | 0.5679 ± 0.3546 | 0.6688 ± 0.7645 | 0.042 * | ab, ac |
| Harmonic-to-noise ratio | 4.9816 ± 3.0341 | 7.3429 ± 2.6551 | 6.3831 ± 1.8776 | 7.2882 ± 2.5396 | 0.004 ** | ab, ac, ad |
| Voice outcome survey | ||||||
| Score of voice outcome survey | 30.3448 ± 12.0957 | 58.0357 ± 18.7251 | 55 ± 21.7945 | 62.1053 ± 25.6209 | <0.001 *** | ab, ac, ad |
| SF-36 | ||||||
| Physical functioning | 60.83 ± 24.88 | 66.03 ± 25.05 | 71.54 ± 20.29 | 68.75 ± 25.64 | 0.053 | ab, ac |
| Role limitation due to physical health problems | 15.83 ± 33.14 | 26.72 ± 38.92 | 36.54 ± 44.85 | 41.25 ± 48.17 | 0.053 | ac, ad |
| Role limitation due to emotional problems | 28.86 ± 39.86 | 48.23 ± 43.28 | 51.22 ± 44.48 | 50 ± 51.3 | 0.034 * | ac |
| Vitality | 47.67 ± 20.79 | 51.03 ± 17.44 | 51.73 ± 19.23 | 57.75 ± 21.12 | 0.001 ** | ac, ad |
| Mental health | 62.13 ± 18.49 | 66.34 ± 13.07 | 66.62 ± 15.76 | 66 ± 19.1 | 0.107 | ac |
| Social functioning | 46.38 ± 25 | 61.76 ± 26.94 | 66.98 ± 26.2 | 71.25 ± 24.03 | <0.001 *** | ab, ac, ad |
| Bodily pain | 62.72 ± 24.72 | 80.02 ± 22.82 | 77.71 ± 21.22 | 79.28 ± 21.59 | 0.003 ** | ab, ac, ad |
| General health perceptions | 41.33 ± 23.19 | 49.83 ± 20.55 | 45.96 ± 20.4 | 50.75 ± 20.41 | 0.360 |
*: p < 0.05; **: p < 0.01; ***: p < 0.001; †: significant comparison pairs; ab: between baseline and 1 month post HIL; ac: between baseline and 3 month post HIL; ad: between baseline and 6 month post HIL. NGGA: normalized glottal gap area.